As such, TXB4-TrkB can be considered as the first in a new generation of brain penetrant agonist antibodies with therapeutic potential in a wide range of neurodegenerative diseases, acute brain and spinal cord injury, and possibly depression. Here, NTRK2 is linked to depressive symptom measurement.